[go: up one dir, main page]

GB0017761D0 - Nucleic acid delivery - Google Patents

Nucleic acid delivery

Info

Publication number
GB0017761D0
GB0017761D0 GBGB0017761.8A GB0017761A GB0017761D0 GB 0017761 D0 GB0017761 D0 GB 0017761D0 GB 0017761 A GB0017761 A GB 0017761A GB 0017761 D0 GB0017761 D0 GB 0017761D0
Authority
GB
United Kingdom
Prior art keywords
nucleic acid
acid delivery
organism
red blood
blood cell
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
GBGB0017761.8A
Other versions
GB2350060A (en
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Gendel Ltd
Original Assignee
Gendel Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gendel Ltd filed Critical Gendel Ltd
Publication of GB0017761D0 publication Critical patent/GB0017761D0/en
Publication of GB2350060A publication Critical patent/GB2350060A/en
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5063—Compounds of unknown constitution, e.g. material from plants or animals
    • A61K9/5068—Cell membranes or bacterial membranes enclosing drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/0057—Photodynamic therapy with a photosensitizer, i.e. agent able to produce reactive oxygen species upon exposure to light or radiation, e.g. UV or visible light; photocleavage of nucleic acids with an agent
    • A61K41/0071—PDT with porphyrins having exactly 20 ring atoms, i.e. based on the non-expanded tetrapyrrolic ring system, e.g. bacteriochlorin, chlorin-e6, or phthalocyanines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6901—Conjugates being cells, cell fragments, viruses, ghosts, red blood cells or viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A61K9/0009—Galenical forms characterised by the drug release technique; Application systems commanded by energy involving or responsive to electricity, magnetism or acoustic waves; Galenical aspects of sonophoresis, iontophoresis, electroporation or electroosmosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • Cell Biology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Hematology (AREA)
  • Botany (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)

Abstract

The invention relates to a method for delivering a nucleic acid to a target site in an organism, comprising the steps of: a) loading a red blood cell with a nucleic acid; b) introducing into the organism the red blood cell loaded with the nucleic acid; and c) causing the nucleic acid to be released from the red blood cell at the target site in the organism.
GB0017761A 1998-07-31 1999-07-30 Nucleic acid delivery Withdrawn GB2350060A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9816583.0A GB9816583D0 (en) 1998-07-31 1998-07-31 Nucleic acid carrier
PCT/GB1999/002490 WO2000007630A1 (en) 1998-07-31 1999-07-30 Nucleic acid delivery

Publications (2)

Publication Number Publication Date
GB0017761D0 true GB0017761D0 (en) 2000-09-06
GB2350060A GB2350060A (en) 2000-11-22

Family

ID=10836418

Family Applications (2)

Application Number Title Priority Date Filing Date
GBGB9816583.0A Ceased GB9816583D0 (en) 1998-07-31 1998-07-31 Nucleic acid carrier
GB0017761A Withdrawn GB2350060A (en) 1998-07-31 1999-07-30 Nucleic acid delivery

Family Applications Before (1)

Application Number Title Priority Date Filing Date
GBGB9816583.0A Ceased GB9816583D0 (en) 1998-07-31 1998-07-31 Nucleic acid carrier

Country Status (3)

Country Link
AU (1) AU5178999A (en)
GB (2) GB9816583D0 (en)
WO (1) WO2000007630A1 (en)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MXPA03000765A (en) * 2000-07-24 2004-05-21 Gendel Ltd Polypeptide delivery ii-2.
WO2002057436A2 (en) * 2001-01-19 2002-07-25 Gendel Limited Red blood cell from a transgenic animal as vehicle for polypeptide delivery
ES2764105T3 (en) 2011-10-17 2020-06-02 Massachusetts Inst Technology Intracellular administration
KR102304167B1 (en) 2013-08-16 2021-09-24 메사추세츠 인스티튜트 오브 테크놀로지 Selective delivery of material to cells
US11111472B2 (en) 2014-10-31 2021-09-07 Massachusetts Institute Of Technology Delivery of biomolecules to immune cells
CN113897285A (en) 2014-11-14 2022-01-07 麻省理工学院 Disruption and field-effected delivery of compounds and compositions into cells
US11125739B2 (en) 2015-01-12 2021-09-21 Massachusetts Institute Of Technology Gene editing through microfluidic delivery
EP4257675A3 (en) * 2015-07-09 2024-01-03 Massachusetts Institute of Technology Delivery of materials to anucleate cells
WO2017041051A1 (en) 2015-09-04 2017-03-09 Sqz Biotechnologies Company Intracellular delivery of biomolecules to cells comprising a cell wall
SG11201809437TA (en) 2016-05-03 2018-11-29 Sqz Biotechnologies Co Intracellular delivery of biomolecules to induce tolerance

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4931276A (en) * 1987-10-30 1990-06-05 Franco Robert S Method for introducing desired agents into red blood cells
WO1991005041A1 (en) * 1989-09-26 1991-04-18 Townes Tim M Erythroid-specific gene expression system
CA2150617C (en) * 1995-02-07 2001-10-30 Universite Laval Nanoerythrosome as bioactive agent carrier

Also Published As

Publication number Publication date
GB9816583D0 (en) 1998-09-30
GB2350060A (en) 2000-11-22
WO2000007630A1 (en) 2000-02-17
AU5178999A (en) 2000-02-28

Similar Documents

Publication Publication Date Title
WO2003093469A3 (en) Methods for delivering nucleic acid molecules into cells and assessment thereof
ATE345682T1 (en) IN VITRO METHOD FOR INTRODUCING NUCLEIC ACIDS INTO A CELL
WO2003080794A3 (en) Inhibition of rna function by delivery of inhibitors to animal cells
CA2190628A1 (en) An implantable containment apparatus for a therapeutical device and method for loading and reloading the device therein
CA2190624A1 (en) An implantable containment apparatus for a therapeutical device and method for loading and reloading the device therein
EP0919622A3 (en) Surface expression of enzyme in gene directed prodrug therapy
WO2005044367A3 (en) Method and apparatus for cell permeabilization
IL195605A0 (en) Combined tumor suppressor gene therapy and chemotherapy in the treatment of neoplasms
EP1235291A3 (en) Fuel cell system
WO1997042975A3 (en) Chitosan related compositions for delivery of nucleic acids into a cell
GB2350060A (en) Nucleic acid delivery
AU6735298A (en) New lipid compounds and compositions containing them which can be used for the transfer of at least one active substance, in particular a polynucleotide, into a target cell and use in gene therapy
WO1997038729A8 (en) In vivo gene transfer methods for wound healing
WO2003045427A3 (en) Pharmaceutical composition for inducing an immune response in a human or animal
IL156780A0 (en) Modular transfection systems
WO2004053103A3 (en) METHOD OF INTRODUCING siRNA INTO ADIPOCYTES
DE60036537D1 (en) COMPOSITIONS FOR GENETHERAPY OF DIABETES
NZ514230A (en) A single step method for lysing cells and cleaving a fusion protein
AU6120600A (en) Herpes simplex virus expressing foreign genes and method for treating cancers therewith
MXPA03000765A (en) Polypeptide delivery ii-2.
WO2000047231A3 (en) Novel antisense inhibition of rad51
GB9917416D0 (en)
EP0763205A4 (en) Nucleic acid sequences controlling lung cell-specific gene expression
CA2441535A1 (en) Methods for delivering nucleic acid molecules into cells and assessment thereof
WO2004079332A3 (en) Composition and method for increasing efficiency of introduction of target substance into cell

Legal Events

Date Code Title Description
WAP Application withdrawn, taken to be withdrawn or refused ** after publication under section 16(1)